|Supplied by:||European Collection of Authenticated Cell Cultures (ECACC)|
|Culture Type:||Cell line|
|Collection:||ECACC General Collection|
|Cell Line Name:||FLYA13|
|Citation Guidance:||If use of this culture results in a scientific publication, it should be cited in the publication as: FLYA13 (ECACC 95091901)|
|Keywords:||Human fibrosarcoma (retroviral packaging cells)|
|Cell Line Description:||FLYA13 has been developed together with FLYRD18 (ECACC catalogue no. 95091902) for packaging of retroviruses, it is especially useful for in vivo gene therapy. Both cell lines have been derived from HT1080 cells (ECACC catalogue no. 85111505). FLYA13 has been transfected with Moloney murine leukaemia virus cores with envelope glycoproteins of amphotropic murine leukaemia virus. This cell line is able to produce human complement-resistant retroviral vectors at titres consistently higher than 1x10,000,000 i.u./ml. Addition of 4µg/ml blasticidin S and 10µg/ml phleomycin into the media may enhance the packaging function. No replication competent virus has been detected in this cell line.|
|Tissue of Origin:||fibrosarcoma|
|GMO Status:||Genetically Modified Organism Class 1 (GMO1)|
Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
|Subculture Routine:||Split sub-confluent cultures (70-80%) 1:20 i.e. seeding at 1x10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO2; 37°C.|
|Culture Medium:||DMEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Dr Y Takeuchi, The Institute of Cancer Research, London|
|References:||J Virol 1995;69:7430|
|Additional Bibliography:||Not specified|
|Patents:||None specified by Depositor|
|Release Conditions:||Yes. All customers are required to complete a Cell line Release Authorisation form|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.